Prognostic significance of molecular markers in oral squamous cell carcinoma: A multivariate analysis

Head and Neck

Volumn 31, Issue 12, 2009, Pages 1544-1556

  Shah, Neelam G ^a   Trivedi, Trupti I ^a   Tankshali, Rajen A ^a   Goswami, Jignesh V ^a   Jetly, Dhaval H ^a   Shukla, Shilin N ^a   Shah, Pankaj M ^a   Verma, Ramtej J ^b  

^a GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

^b GUJARAT UNIVERSITY   (India)

Author keywords

EGFR Stat3 downstream cascade; Immunohistochemistry; Oral squamous cell carcinoma; p16; p53; Prognosis; Stat3

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; STAT3 PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; ONCOGENE H RAS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT DISEASE; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; CYCLIN D; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDIA; KI-67 ANTIGEN; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 72449146809     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21126     Document Type: Article

References (48)

1. Zbaren P, Lehmann W. Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy. Arch Otolaryngol Head Neck Surg 1987;113:762-764.
2. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin 2002;52:195-215.
3. Cohen EEW. Novel therapeutic targets in squamous cell carcinoma of the head and neck. Semin Oncol 2004;31:755-768. (Pubitemid 39602681)
4. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma 3: clinicopathological applications. Oral Oncol 2000;36:404-413. (Pubitemid 30645974)
5. Gleich LL, Salamone FN. Molecular genetics of head and neck cancer. Cancer Control 2002;9:369-378. (Pubitemid 35204459)
6. Nagpal JK, Das BR. Oral cancer: reviewing the present understanding of its molecular mechanisms and exploring the future directions for its effective management. Oral Oncol 2003;39:213-221.
7. Hardisson D. Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2003;260:502-508. (Pubitemid 37363578)
8. Nagai MA. Genetic alterations in head and neck squamous cell carcinomas. Braz J Med Biol Res 1999;32:897-904. (Pubitemid 129539481)
9. Masuda M, Suzui M, Yasumatu R, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002;62:3351-3355.
10. Klosek SK, Nakashiro KI, Hara S, Li C, Shintani S, Hamakava H. Constitutive activation of Stat3 correlates with increased expression of the c-Met/HGF receptor in oral squamous cell carcinoma. Oncol Rep 2004;12:293-296.
11. Nguyen DC, Parsa B, Close A, Magnusson B, Crowe DL, Sinha UK. Overexpression of cell cycle regulatory proteins correlates with advanced tumor stage in head and neck squamous cell carcinomas. Int J Oncol 2003;22:1285-1290.
12. Kiaris H, Spandidos DA, Jones AS, Vaughan ED, Field JK. Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. Br J Cancer 1995;72:123-128.
13. Todd R, Donoff RB, Wong DTW. The molecular biology of oral cancer: towards a tumor progression model. J Oral Maxillofac Surg 1997;55:613-623. (Pubitemid 27259789)
14. McDonald JS, Jones H, Pavelic ZP, Pavelic LJ, Stambrook PJ, Gluckman JL. Immunohistochemical detection of the H-ras, K-ras, and N-ras oncogenes in squamous cell carcinoma of the head and neck. J Oral Pathol Med 1994;23:342-346. (Pubitemid 2150698)
15. Yarbrough WG, Shores C, Witsell DL, Weissler MC, Fidler ME, Gilmer TM. Ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope 1994;104:1337-1347. (Pubitemid 24346961)
16. Yuen PW, Man M, Lam KY, Kwong YL. Clinicopathologic significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. J Clin Pathol (Lond) 2002;55:58-60. (Pubitemid 34081683)
17. Lo Muzio L, Falaschini S, Farina A, et al. Bcl-2 as prognostic factor in head and neck squamous cell carcinoma. Oncol Rep 2005;15:249-255. (Pubitemid 41415103)
18. Bova RJ, Quinn DI, Nankervis JS, et al. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999;5:2810-2819.
19. de Vicente JC, Herrero-Zapatero A, Fresno MF, Lopez- Arranz JS. Expression of cyclin D1 and Ki-67 in squamous cell carcinoma of the oral cavity: clinicopathologic and prognostic significance. Oral Oncol 2002;38:301-308. (Pubitemid 34442553)
20. Raju B, Mehrotra R, Oijordsbakken G, Al-Sharabi AK, Vasstrand EN, Ibrahim SO. Expression of p53, cyclin D1 and Ki-67 in pre-malignant and malignant oral lesions: association with clinicopathologic parameters. Anticancer Res 2005;25:4699-4706. (Pubitemid 41729533)
21. Jayasurya R, Sathyan KM, Lakshminarayanan K, et al. Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma. Mod Pathol 2005;18:1056-1066. (Pubitemid 41224496)
22. Shah NG, Trivedi TI, Tankshali RA, et al. Molecular alterations in oral carcinogenesis: significant risk predictors in malignant transformation and tumor progression. Int J Biol Markers 2007;22:132-143.
23. UICC. TNM classification of malignant tumors. UICC Techn Rep Ser 1980;5:2.
24. Broders AC. Microscopic grading of cancer. Surg Clin North Am 1941;21:947-962.
25. Shah NG, Trivedi TI, Tankshali RA, et al. Stat3 expression in oral squamous cell carcinoma: association with clinicopathologic parameters and survival. Int J Biol Markers 2006;21:175-183.
26. de Oliveira LR, Ribeiro-Silva A, Zucoloto S. Prognostic impact of p53 and p63 immunoexpression in oral squamous cell carcinoma. J Oral Pathol Med 2007;36:191-197. (Pubitemid 46495983)
27. Geisler SA, Olshan AF, Weissler MC, et al. p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 2002;8:3445-3453.
28. Shin DM, Lee JS, Lippman SM, et al. p53 expression: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:519-529. (Pubitemid 26118722)
29. Kapranos N, Stathopoulos GP, Manolopoulos L, et al. p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. Anticancer Res 2001;21:521-528.
30. Ravi D, Ramdas K, Mathew BS, Panikkar KR, Nair MK, Pillai MR. Apoptosis, angiogenesis and proliferation: trifunctional measure of tumor response to radiotherapy for oral cancer. Oral Oncol 2001;37:164-171. (Pubitemid 32146663)
31. Shiraki M, Odajima T, Ikeda T, et al. Combined expression of p53, cyclin D1 and epidermal growth factor receptor improves estimation of prognosis in curatively resected oral cancer. Mod Pathol 2005;18:1482-1489. (Pubitemid 41509403)
32. Homma E, Furuta Y, Oridate N, et al. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res 1999;5:801-806. (Pubitemid 29180831)
33. Teni T, Pawar S, Sanghvi V, Saranath D. Expression of Bcl-2 and Bax in chewing tobacco-induced oral cancers and oral lesions from India. Pathol Oncol Res 2002;8:109-114. (Pubitemid 34988060)
34. Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 2000;97:4227-4232. (Pubitemid 30226115)
35. Nagpal JK, Mishra R, Das BR. Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer 2002;94:2393-2400. (Pubitemid 34457120)
36. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-1635.
37. Takahashi R, Tanaka S, Kitadai Y, et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 2003;64:266-274. (Pubitemid 36438812)
38. Pande P, Soni S, Kaur J, et al. Prognostic factors in betel and tobacco related oral cancer. Oral Oncol 2002;38:491-499. (Pubitemid 34759989)
39. Miracca EC, Kowalski LP, Nagai MA. High prevalence of p16 genetic alterations in head and neck tumors. Br J Cancer 1999;81:677-683. (Pubitemid 29458865)
40. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602. (Pubitemid 27152402)
41. Eilers M, Picard D, Yamamoto KR, Bishop JM. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature 1989;340:66-68. (Pubitemid 19172604)
42. Heikkila R, Schwab G, Wickstrom E, et al. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature 1987;328:445-449. (Pubitemid 17097780)
43. Waters CM, Littlewood TD, Hancock DC, Moore JP, Evan GI. c-myc protein expression in untransformed fibroblasts. Oncogene 1991;5:797-805.
44. Bowmen T, Garcia R, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-2488.
45. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002;109:1139-1142.
46. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
47. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-115. (Pubitemid 29077388)
48. Boyle JO, Hakim J, Koch W, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993;53:4477-4480. (Pubitemid 23304366)